JPS5817470B2 - Synquina morpholine - Google Patents

Synquina morpholine

Info

Publication number
JPS5817470B2
JPS5817470B2 JP14308075A JP14308075A JPS5817470B2 JP S5817470 B2 JPS5817470 B2 JP S5817470B2 JP 14308075 A JP14308075 A JP 14308075A JP 14308075 A JP14308075 A JP 14308075A JP S5817470 B2 JPS5817470 B2 JP S5817470B2
Authority
JP
Japan
Prior art keywords
group
acid
general formula
novel
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP14308075A
Other languages
Japanese (ja)
Other versions
JPS5268187A (en
Inventor
亀野義人
高島義典
砂川洵
山本久夫
勝部純基
小島淳之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Priority to JP14308075A priority Critical patent/JPS5817470B2/en
Publication of JPS5268187A publication Critical patent/JPS5268187A/en
Publication of JPS5817470B2 publication Critical patent/JPS5817470B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 本発明は一般式〔I〕 〔式中、R1は水素原子または低級アルキル基を表わし
、R2は低級アルキニル基、低級ヒドロキシアルキル基
まだは低級ポリハロアルキル基を表わし、AはC2〜3
の直鎖または分枝のアルキレン鎖を表わし、Bは−CH
2CH2一基または−CH=CH−基を表わし、C1オ
ヨびC2は1゜2−フェニレン基ヲ表ワス。
DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the general formula [I] [wherein R1 represents a hydrogen atom or a lower alkyl group, R2 represents a lower alkynyl group, a lower hydroxyalkyl group, or a lower polyhaloalkyl group, is C2~3
represents a straight or branched alkylene chain, and B is -CH
It represents a 2CH2 group or a -CH=CH- group, and C1 and C2 represent a 1°2-phenylene group.

〕で表わされる新規モルホリン誘導体の新規製造法に関
する。
This invention relates to a new method for producing a novel morpholine derivative represented by

更に詳しくは一般式(I[) 〔式中、R1,R2,A、B、C1およびC2は先と同
じ意味を有する。
More specifically, general formula (I[) [wherein R1, R2, A, B, C1 and C2 have the same meanings as above].

〕で表わされる新規アリル−アルカノールアミン誘導体
を酸触媒の存在下、分子内閉環させることを特徴とする
前記新規モルホリン誘導体CI)の新規製造法である。
This is a novel method for producing the novel morpholine derivative CI), characterized in that the novel allyl-alkanolamine derivative represented by the following formula is subjected to intramolecular ring closure in the presence of an acid catalyst.

ここで、C0およびC2で表わされる1、2−フェニレ
ン基ハ通常の1,2−フェニレン基< 6 >のみな
らず、・・ロゲン原子、低級アルキル基、低級アルコキ
シル基等の置換基を有するカ、実質的に1,2−フェニ
レン基と等価の置換1、?−フェニレン基モ表ワス。
Here, the 1,2-phenylene group represented by C0 and C2 is not only a normal 1,2-phenylene group <6>, but also a group having a substituent such as a rogen atom, a lower alkyl group, or a lower alkoxyl group. , a substitution 1, substantially equivalent to a 1,2-phenylene group? - Phenylene group base.

一般式CI)で表わさnる本発明の目的化合物は10,
11−ジヒドロ−5H−ジベンゾ(atd〕シクロヘプ
テン、5H−ジベンゾ(a、、d)シクロヘプテン等の
二環性骨格にモルホリノメチリデン基が結合した新規な
骨格を有する新規化合物群であり、本発明者らによシ初
めて合成された化合物群である。
The target compound of the present invention represented by general formula CI) is 10,
This is a group of novel compounds having a novel skeleton in which a morpholinomethylidene group is bonded to a bicyclic skeleton such as 11-dihydro-5H-dibenzo(atd)cycloheptene and 5H-dibenzo(a,,d)cycloheptene. This is a group of compounds that were synthesized for the first time.

すなわち、本発明者らはかねて中枢神経系関与性の新し
い医薬の創製を目脂して、各種の二環性化合物の合成研
究に鋭意従事してきたが、此度一般式(II)で表わさ
扛る新規アリル−アルカノールアミン誘導体を酸触媒で
扱うことにより分子内閉環反応が進行し、一般式〔1〕
で表わさ扛る本発明の目的化合物が非常に高収率で得ら
れることを見出し、本発明方法に至った。
That is, the present inventors have been earnestly engaged in research on the synthesis of various bicyclic compounds with the aim of creating new drugs that involve the central nervous system. By treating the novel allyl-alkanolamine derivative with an acid catalyst, an intramolecular ring-closing reaction proceeds, resulting in the formation of the general formula [1]
It was discovered that the target compound of the present invention, represented by

かかる分子内閉環反応を用いる新規な三項性モルホリン
誘導体CI、lの合成は他に類例をみない全く独自な方
法である。
The synthesis of the novel triadic morpholine derivative CI,l using such an intramolecular ring-closing reaction is an unprecedented and completely unique method.

さらにまた、かくして得られた本発明化合物CI)は中
枢神経系ないし自律神経系に対し各種の興味ある薬理作
用を有し、たとえば強い抗テトラベナジン作用を有する
ので、向精神薬特に抗うつ剤として非常に有用であるこ
とが本発明者らの研究により明らかにさ扛た。
Furthermore, the thus obtained compound CI) of the present invention has various interesting pharmacological actions on the central nervous system or autonomic nervous system, such as strong anti-tetrabenazine action, and therefore is very useful as a psychotropic drug, especially as an antidepressant. It has been revealed through research by the present inventors that this method is useful for

従って、本発明の趣旨とするところのものは新規にして
医薬的価値の極めて高い一般式CI)で表わされる化合
物群の有利な製造法を提供せんとするものである。
Accordingly, the object of the present invention is to provide a new and advantageous method for producing compounds represented by the general formula CI) which are of extremely high pharmaceutical value.

本発明方法は一般式(n)で表わされるアリル−アルカ
ノールアミン誘導体を直接または不活性溶媒中、酸触媒
と接触させることにより達成される。
The method of the present invention is achieved by contacting the allyl-alkanolamine derivative represented by general formula (n) with an acid catalyst, either directly or in an inert solvent.

用いられる酸触媒としては各種のものが挙げられるが、
塩酸、臭素酸、硫酸、硝酸、リン酸、ポリリン酸等で代
表される無機酸、メタンスルホン酸、ベンゼンスルホン
酸、トルエンスルホン酸、蓚酸、蟻酸、トリフルオロ酢
酸等で代表される各種の酸性度の強い有機酸、あるいは
塩化アルミニウム、三弗化硼素(およびその各種の錯体
)等で代表されるルイス酸が好適なものとして挙げられ
る。
There are various types of acid catalysts that can be used, but
Inorganic acids represented by hydrochloric acid, bromic acid, sulfuric acid, nitric acid, phosphoric acid, polyphosphoric acid, etc. Various acids represented by methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, oxalic acid, formic acid, trifluoroacetic acid, etc. Suitable examples include strong organic acids, or Lewis acids represented by aluminum chloride, boron trifluoride (and various complexes thereof), and the like.

本反応は原料化合物(II)と酸触媒を直接接触させる
ことも可能であるが、場合により反応に関与しない不活
性溶媒の存在下酸触媒と反応させることができる。
In this reaction, the raw material compound (II) can be brought into direct contact with an acid catalyst, but depending on the case, the reaction can be carried out with an acid catalyst in the presence of an inert solvent that does not participate in the reaction.

不活性溶媒としては酢酸、クロロホルム、ヘキャン、エ
ーテル、ベンゼン等が挙ケられる。
Examples of inert solvents include acetic acid, chloroform, hecane, ether, and benzene.

本反応は室温で行なうことも可能であるが、必要に応じ
て冷却まだは加温して反応を抑制または促進させること
ができる。
Although this reaction can be carried out at room temperature, the reaction can be suppressed or accelerated by cooling or heating, if necessary.

反応終了後は通常の有機化学的手法により成績体をとり
だすことができる。
After the reaction is completed, the resultant can be taken out using conventional organic chemistry techniques.

本発明方法によって得られる前記一般式CI)の化合物
は、アミン誘導体であるので、所望に応じて生理的に無
害の各種の無機酸および有機酸たとえば塩酸、硫酸、臭
化水素酸、酢酸、蓚酸、クエン酸、リンゴ酸、酒石酸、
フマール酸、コハク酸などと酸附加塩を形成することが
できる。
Since the compound of general formula CI) obtained by the method of the present invention is an amine derivative, various physiologically harmless inorganic and organic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, acetic acid, and oxalic acid may be used as desired. , citric acid, malic acid, tartaric acid,
Acid salts can be formed with fumaric acid, succinic acid, etc.

なお、本発明の原料化合物(II)は本発明者等により
初めて合成さf′Lだ新規化合物であるが、たとえば下
記合成経路により合成することができる。
Although the starting material compound (II) of the present invention is a novel compound f'L synthesized for the first time by the present inventors, it can be synthesized, for example, by the following synthetic route.

〔式中、R,、R2、A、B、C1およびC2は先と同
じ意味を有し、M、M’はマグネシウム/・ライドまた
はアルカリ金属を表わす。
[In the formula, R,, R2, A, B, C1 and C2 have the same meanings as above, and M and M' represent magnesium/.ride or an alkali metal.

〕すなわち、一般式(III)で表わさ扛る10,11
−ジヒドロ−5H−ジベンゾ(a d)シクロヘプテ
ン−5−オン誘導体ないし5H−ジベンゾ(a d)
シクロへブテン−5−オン誘導体を出発原料とし、これ
に一般式(IV)で表わされるプロパルギルアミン誘導
体の金属化合物を反応させるか、もしくは一般式(V)
で表わされるエチニルカルビノール誘導体に一般式〔■
〕で表わされるアミン誘導体を、一般式〔■〕で表わさ
れるアルデヒド誘導体の存在下、マンニッヒ反応型に縮
合させることによって得られる一般式(Vl)で表わさ
れる新規プロパルギル−アルカノールアミン誘導体の炭
素−炭素三重結合を部分還元して二重結合とすることに
より効果的に得ることができる。
] That is, 10,11 represented by the general formula (III)
-dihydro-5H-dibenzo(ad) cyclohepten-5-one derivative to 5H-dibenzo(ad)
A cyclohebuten-5-one derivative is used as a starting material, and a metal compound of a propargylamine derivative represented by the general formula (IV) is reacted with it, or a metal compound of a propargylamine derivative represented by the general formula (V) is reacted with the cyclohebuten-5-one derivative.
The general formula [■
] Carbon-carbon of a novel propargyl-alkanolamine derivative represented by the general formula (Vl) obtained by condensing the amine derivative represented by the following in a Mannich reaction type in the presence of an aldehyde derivative represented by the general formula [■] It can be effectively obtained by partially reducing a triple bond to form a double bond.

前記一般式で表わされる化合物において、低級アルキル
基としては、たとえばメチル基、エチル基、n−プロピ
ル基、1so−プロピル基などを含み、低級アルキニル
基としては、たとえばクロパルギル基、ブヂニル基など
を含み、低級ヒドロキシアルキル基としては、たとえば
2−ヒドロキシエチル基、3−ヒドロキシプロピル基な
どを含み、低級ポリ・・ロアルキル基としては、たとえ
ば2゜2.2−MJフルオロエチル基などを含む。
In the compound represented by the above general formula, the lower alkyl group includes, for example, a methyl group, ethyl group, n-propyl group, 1so-propyl group, etc., and the lower alkynyl group includes, for example, a clopargyl group, a butynyl group, etc. Examples of the lower hydroxyalkyl group include a 2-hydroxyethyl group and a 3-hydroxypropyl group, and examples of the lower polyalkyl group include a 2°2.2-MJ fluoroethyl group.

以下に代表的な実施例を記載するが、本発明方法はもと
より、これに限定されるものではない。
Typical examples will be described below, but the method of the present invention is not limited thereto.

実施例 I N−(2−ヒドロキシエチル)−N−(3−(10,1
1−ジヒドロ−5H−ジベンゾ(ajd)シクロヘプテ
ン−5−イル)アリルシー2−エタノールアミン(90
rrLg)を氷酢酸(1M)に溶かし、濃塩酸(11r
Ll)を加えた後室温で3.5時間攪拌した。
Example I N-(2-hydroxyethyl)-N-(3-(10,1
1-dihydro-5H-dibenzo(ajd)cyclohepten-5-yl)allylic 2-ethanolamine (90
rrLg) was dissolved in glacial acetic acid (1M) and concentrated hydrochloric acid (11r
After adding Ll), the mixture was stirred at room temperature for 3.5 hours.

その後溶液を濃縮し、30%苛性ソーダ水にて中和の後
、ベンゼンにて抽出し、乾燥後ベンゼンを留去したとこ
ろ油状物が得られ、これをクロマト法にて精製したとこ
ろ、目的(7)5−(4−(2−ヒドロキシエチル)モ
ルホリン−2−イル〕メチリデンー10.11−ジヒド
ロ−5H−ジベン7”(a、d)シクロヘプテンが油状
物として得ら扛だ。
Thereafter, the solution was concentrated, neutralized with 30% caustic soda water, extracted with benzene, dried and distilled off the benzene to obtain an oil, which was purified by chromatography to obtain the objective (7 ) 5-(4-(2-hydroxyethyl)morpholin-2-yl)methylidene-10.11-dihydro-5H-diben 7'' (a, d) cycloheptene was obtained as an oil.

塩酸塩の融点210〜212℃。Melting point of hydrochloride: 210-212°C.

なお、実施例1中のN−(2−ヒドロキシエチル)−N
−(3−(10,11−ジヒド0−5H−ジベンゾ(a
td)シクロへブテン−5−イ# )アリル)−2−エ
タノールアミンを一般式〔■〕の適当な出発物質の当モ
ルで置き換える以外は実施例1の方法と同様にして次の
化合物群が得られた。
In addition, N-(2-hydroxyethyl)-N in Example 1
-(3-(10,11-dihydro0-5H-dibenzo(a
The following compound group was prepared in the same manner as in Example 1 except that td) cyclohebutene-5-y #) allyl)-2-ethanolamine was replaced with the equivalent mole of the appropriate starting material of the general formula [■]. Obtained.

Claims (1)

【特許請求の範囲】 1 一般式 〔式中、R7は水素原子または低級アルキル基を表わし
、R2は低級アルキニル基、低級ヒドロキシアルキル基
または低級ポリハロアルキル基ヲ表わし、AばC2〜3
の直鎖または分枝のアルキレン鎖を表わし、Bは−CH
2CH2一基または−CH=CH−基を表わし、C1お
よびC2は1゜2−フェニレン基ヲ表ワす。 〕で表わされるアリル−アルカノ−ルアオン誘導体を酸
触媒の存在下分子内閉環させることを特徴とする一般式 〔式中、R1、R2、A、B、C1およびC2は先と同
じ意味を有する。 〕で表わされる新規モルホリン誘導体の新規製造法。
[Scope of Claims] 1 General formula [In the formula, R7 represents a hydrogen atom or a lower alkyl group, R2 represents a lower alkynyl group, a lower hydroxyalkyl group, or a lower polyhaloalkyl group, and A is a C2-3
represents a straight or branched alkylene chain, and B is -CH
2CH2 represents a single group or a -CH=CH- group, and C1 and C2 represent a 1°2-phenylene group. [In the formula, R1, R2, A, B, C1 and C2 have the same meanings as above. ] A novel method for producing a novel morpholine derivative.
JP14308075A 1975-11-29 1975-11-29 Synquina morpholine Expired JPS5817470B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14308075A JPS5817470B2 (en) 1975-11-29 1975-11-29 Synquina morpholine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14308075A JPS5817470B2 (en) 1975-11-29 1975-11-29 Synquina morpholine

Publications (2)

Publication Number Publication Date
JPS5268187A JPS5268187A (en) 1977-06-06
JPS5817470B2 true JPS5817470B2 (en) 1983-04-07

Family

ID=15330437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14308075A Expired JPS5817470B2 (en) 1975-11-29 1975-11-29 Synquina morpholine

Country Status (1)

Country Link
JP (1) JPS5817470B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103274990B (en) 2007-12-03 2015-03-11 株式会社半导体能源研究所 Carbazole derivative, and light-emitting element, light-emitting device, and electronic device

Also Published As

Publication number Publication date
JPS5268187A (en) 1977-06-06

Similar Documents

Publication Publication Date Title
US3420851A (en) Novel dibenzoxepines
JP2637737B2 (en) New drugs
JP2562503B2 (en) Propenone oxime ethers, a method for producing the same, and a pharmaceutical composition containing the same
JP2014514292A (en) Reductive amination process for producing dronedarone using amine intermediate compounds
Biel et al. Antispasmodics. I. Substituted Acetic Acid Esters of 1-Alkyl-3-hydroxypiperidine1
US3819628A (en) 2-phenyl-4-substituted amino-quinazolines and nitrates thereof
EA005491B1 (en) Method for the preparation of citalopram
US4091115A (en) 7-Amino-benzocycloheptenes
US2919271A (en) 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines
KR101166280B1 (en) Process for preparation of citalopram and enantiomers
JPS6360985A (en) 4,7-dihydropyrazolo(1,5-a)pyrimidine derivative
FR2496653A1 (en) Aminoalkyl di:hydro-naphthalene, isoquinoline and benzoxazepine cpds. - useful as analgesics and antidepressants
JPS5817470B2 (en) Synquina morpholine
Evanguelidou et al. Acid-Catalyzed Condensation of a Reissert Compound with Acrylonitrile
JPS58116434A (en) Substituted phenoxyalkanol amines and phenoxyalkanol-cycloalkylamines
US4705807A (en) Amine derivatives
US3256278A (en) N-hydroxy ethyl-ortho acetyl and carbalkoxy amino phenyl-glyoxamides and process formaking 2-orthoamino phenyl-morpholines
WO2020171073A1 (en) Method for producing benzazepine derivative and intermediate of same
US3166570A (en) Derivatives of benzo[e] isoindoline and their preparation
JPH0319236B2 (en)
JPS5817469B2 (en) Shinki Namorpholine Yudo Taino Shinki Seizouhou
US3389177A (en) 5-(3&#39;-aminopropyl)-11, 12-dihydro-dibenzo [a, e] cyclooctenes and salts thereof
KR930006777B1 (en) Pyrido |1,2-a¨ indoles
US3293251A (en) Rearrangement process for j,b-diaza- bicyclo-(j,z,i)-octane derivatives
US3127405A (en) I-phenylalkyl